Pertussis is an endemic disease in the EU/EEA and worldwide. Every three to five years, larger epidemics are expected even with high vaccination coverage.
In 2019, the hajj will take place between 9 and 14 August. The risk for EU/EEA citizens to become infected with communicable diseases during the 2019 hajj is considered low, thanks to the vaccination requirements for travelling to Makkah (Mecca) and the Saudi Arabian preparedness plans that address the management of health hazards during and after hajj.
On 31 August 2016 the autonomous Community of Madrid, Spain, reported two cases of infection with Crimean–Congo haemorrhagic fever (CCHF) virus. This document assesses the risk associated with the occurrence of two cases of Crimean–Congo haemorrhagic fever in Spain.
This rapid risk assessment describes the epidemiological situation of diphtheria surrounding this case of toxigenic respiratory diphtheria reported in Belgium.
This Rapid Risk Assessment focuses on acellular pertussis-containing combination vaccines used in national vaccination programmes in the EU/EEA Member States.
Early in 2015, a shortage of acellular pertussis-containing vaccines was brought to the attention of ECDC. This risk assessment provides a detailed list of mitigation options available to Member States.
ECDC and EFSA have assessed the risk to the EU/EEA posed by a fatal human case of Bacillus anthracis infection in Bulgaria and concluded that this event represents a negligible risk to other EU/EEA countries.
This rapid risk assessment concludes that there is currently no indication that these cases represent a significant outbreak of diphtheria among refugees in Europe.